Faculty of Chemistry, Adam Mickiewicz University, Grunwaldzka St. 6, 60-780 Poznań, Poland.
Bioorg Med Chem. 2011 Nov 1;19(21):6375-82. doi: 10.1016/j.bmc.2011.08.069. Epub 2011 Sep 5.
A series of novel N-alkyl 5'-chloromethylphosphonates of 3'-azido-3'-deoxythymidine (6-15) was synthesized by means of phosphonylation of 3'-azido-3'-deoxythymidine (4) with P-chloromethylphosphonic ditriazolide (3) followed by a reaction with the appropriate amine. The synthesized phosphonamidates 6-15 were evaluated for their cytotoxic activity in two human cancer cell lines: oral (KB) and breast (MCF-7) using the sulforhodamine B (SRB) assay. The highest activity in KB human cancer cells was displayed by phosphonamidate 8 (IC(50)=5.8 μg/mL), however, this compound was less potent than the parent AZT (IC(50)=3.1 μg/mL). Phosphonamidate 10 showed only moderate activity (IC(50)=12.1 μg/mL) whereas the other phosphonamidates proved inactive. Similarly, the highest activity in MCF-7 human cancer cells was displayed by phosphonamidate 8 (IC(50)=3.7 μg/mL) but it proved somewhat less active than AZT (IC(50)=2.6 μg/mL). Some activity was also displayed by phosphonamidate 10 (IC(50)=12.8 μg/mL) but the other phosphonamidates were found inactive. Hydrolysis studies indicate that the synthesized phosphonamidates are likely to act as prodrugs of the parent nucleoside (AZT). Transport measurements showed that the most active phosphonamidates (8 and 10) were able to permeate across the intestinal epithelium in vitro. The apparent permeability coefficients determined in Caco-2 cell monolayers indicated that these compounds could be moderately absorbed in humans.
一系列新型的 N-烷基 5'-氯甲基膦酸酯 3'-叠氮基-3'-去氧胸苷(6-15)是通过 3'-叠氮基-3'-去氧胸苷(4)与 P-氯甲基膦酸二叠氮化物(3)的膦酰化反应,然后与适当的胺反应合成的。合成的磷酰胺酯 6-15 在用磺基罗丹明 B(SRB)测定法在两种人类癌细胞系(口腔(KB)和乳腺(MCF-7))中进行了细胞毒性活性评价。在 KB 人类癌细胞中显示出最高活性的磷酰胺酯 8(IC(50)=5.8μg/mL),但该化合物比母体 AZT(IC(50)=3.1μg/mL)的活性稍低。磷酰胺酯 10 仅显示出中等活性(IC(50)=12.1μg/mL),而其他磷酰胺酯则没有活性。同样,在 MCF-7 人类癌细胞中显示出最高活性的磷酰胺酯 8(IC(50)=3.7μg/mL),但其活性比 AZT(IC(50)=2.6μg/mL)稍低。磷酰胺酯 10 也显示出一定的活性(IC(50)=12.8μg/mL),但其他磷酰胺酯没有活性。水解研究表明,合成的磷酰胺酯可能是母体核苷(AZT)的前药。转运研究表明,最活跃的磷酰胺酯(8 和 10)能够在体外穿透肠上皮。在 Caco-2 细胞单层中确定的表观渗透系数表明,这些化合物在人体中可能会被适度吸收。